Anti-doping testing raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-18 and is reviewed periodically as new material appears.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
===== U.S. government think tanks ===== Government think tanks are also important in the United States, particularly in the security and defense field. These include the Center for Technology and National Security Policy at the National Defense University, the Center for Naval Warfare Studies at the Naval War College, and the Strategic Studies Institute at the U.S. Army War College. The government funds, wholly or in part, activities at approximately 30 Federally Funded Research and Development Centers (FFRDCs). FFRDCs, are unique independent nonprofit entities sponsored and funded by the United States government to meet specific long-term technical needs that cannot be met by any other single organization. FFRDCs typically assist government agencies with scientific research and analysis, systems development, and systems acquisition. They bring together the expertise and outlook of government, industry, and academia to solve complex technical problems. These FFRDCs include the RAND Corporation, the MITRE Corporation, the Institute for Defense Analyses, the Aerospace Corporation, the MIT Lincoln Laboratory, and other organizations supporting various departments within the United States Government. Similar to the above quasi-governmental organizations are Federal Advisory Committees. These groups, sometimes referred to as commissions, are a form of think tank dedicated to advising the US Presidents or the Executive branch of government. They typically focus on a specific issue and as such, might be considered similar to special interest groups.
where Δσ is the change in free energy of the particle, σps is the surface potential between the particle and interface, σpl is the potential between the particle and the liquid phase and σsl is the surface potential between the solid and liquid phases. This expression is valid at low solidification velocities, when the system is shifted only slightly from equilibrium. At high solidification velocities, kinetics must also be taken into consideration. There will be a liquid film between the front and particle to maintain constant transport of the molecules which are incorporated into the growing crystal. When the front velocity increases, this film thickness (d) will decrease due to increasing drag forces. A critical velocity (vc) occurs when the film is no longer thick enough to supply the needed molecular supply. At this speed the particle will be engulfed. Most authors express vc as a function of particle size where
Choh Hao Li (sometimes Cho Hao Li) (Chinese: 李卓皓; pinyin: Lǐ Zhuōhào; April 21, 1913 – November 28, 1987) was a Chinese-born American biochemist who discovered in 1966 that human pituitary growth hormone (somatotropin) consists of a chain of 256 amino acids. In 1970, he succeeded in synthesizing this hormone, the largest protein molecule synthesized up to that time.
Sources: en.wikipedia.org
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) One of the 17 institutes that make up the National Institutes of Health, an agency of the Public Health Service. Necrobiosis lipoidica diabeticorum A skin condition usually on the lower part of the legs. The lesions can be small or extend over a large area. They are usually raised, yellow, and waxy in appearance and often have a purple border. Young women are most often affected. This condition occurs in people with diabetes, or it may be a sign of diabetes. It also occurs in people who do not have diabetes. Neovascularization When new, tiny blood vessels grow in a new place, for example, out from the retina. See also: Diabetic retinopathy. Nephrologist a physician specializing in diseases of and treatment of the kidneys Nephropathy Disease of the kidneys caused by damage to the small blood vessels or to the units in the kidneys that clean the blood. People who have had diabetes for a long time may have kidney damage. Nerve conduction studies Tests to determine nerve function; can detect early neuropathy. Neurologist a physician specializing in diseases of and treatment of the nervous system. Neuropathy nerve damage. In a diabetic context, a chronic complication of diabetes. Damage usually appears in the longest nerves, for reasons we only dimly understand, resulting in loss of sensation to the feet and lower legs. The damage is almost always bilateral. Loss of reflexes is also common. Neuropathy can also affect the hands, motor nerves, and the autonomic system.
Ansuvimab was developed by the Vaccine Research Center with support of the United States National Institutes of Health and the Defense Advanced Projects Agency. The heavy and light chain sequences of ansuvimab mAb were cloned into CHO cell lines to enable large-scale production of antibody product for use in humans. In early 2018, a Phase 1 clinical trial of ansuvimab's safety, tolerability and pharmacokinetics was conducted by Dr. Martin Gaudinski within the Vaccine Research Center Clinical Trials Program that is led by Dr. Julie E. Ledgerwood. The study was performed in the United States at the NIH Clinical Center and tested single dose infusions of ansuvimab infused over 30 minutes. The study showed that ansuvimab was safe, had minimal side effects and had a half-life of 24 days. A license for ansuvimab was obtained by Ridgeback Biotherapeutics in 2018, from the National Institutes of Health-National Institute of Allergy and Infectious Diseases. Ansuvimab was given orphan drug status in May 2019 and March 2020.
Sample Preparation: DNA is extracted from a sample (e.g., blood) and cut into fragments of 50 to 200 kilo base-pairs long. Barcode Sequencing: each DNA fragment is labelled with a unique barcode through a process known as "Gel Bead-In Emulsion" (GEM). Library Preparation: barcoded DNA fragments are amplified with PCR to generate sequencing libraries. Sequencing: with Illumina next-generation sequencing technology, generate millions to billions of short sequence reads that represent fragments of the original DNA molecules. Barcode Processing: group short reads to longer fragments based on barcodes. Downstream Analysis: processed reads are aligned to a reference genome, or used for de novo assembly of complex genomes, haplotype phasing, or identification of structural variations.
== Spatial xenon oscillations == Large thermal reactors with low flux coupling between regions may experience spatial power oscillations because of the non-uniform presence of xenon-135. Xenon-induced spatial power oscillations occur as a result of rapid perturbations to power distribution that cause the xenon and iodine distribution to be out of phase with the perturbed power distribution. This results in a shift in xenon and iodine distributions that causes the power distribution to change in an opposite direction from the initial perturbation. The instantaneous production rate of xenon-135 is dependent on the iodine-135 concentration and therefore on the local neutron flux history. On the other hand, the destruction rate of xenon-135 is dependent on the instantaneous local neutron flux. The combination of delayed generation and high neutron-capture cross section produces a diversity of impacts on nuclear reactor operation. The mechanism is described in the following four steps.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.